US 12,311,020 B2
Immunogenic compositions against influenza
Michael J. Moser, Madison, WI (US); Yasuko Hatta, Madison, WI (US); and Pamuk Bilsel, Madison, WI (US)
Assigned to FluGen, Inc., Madison, WI (US)
Filed by FluGen, Inc., Madison, WI (US)
Filed on May 18, 2022, as Appl. No. 17/747,713.
Application 17/747,713 is a continuation of application No. 16/488,906, granted, now 11,344,616, previously published as PCT/US2018/019653, filed on Feb. 26, 2018.
Claims priority of provisional application 62/464,019, filed on Feb. 27, 2017.
Prior Publication US 2023/0099147 A1, Mar. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/145 (2006.01); A61K 39/295 (2006.01); C12N 7/00 (2006.01)
CPC A61K 39/145 (2013.01) [A61K 39/295 (2013.01); C12N 7/00 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16171 (2013.01); C12N 2760/16234 (2013.01); C12N 2760/16271 (2013.01)] 8 Claims
OG exemplary drawing
 
1. An immunogenic composition, wherein the composition is a quadrivalent composition consisting of:
a) two engineered attenuated influenza A viruses consisting of:
i) H1N1 having a mutant M2 gene comprising SEQ ID NO: 1, and
ii) H3N2 having a mutant M2 gene comprising SEQ ID NO: 1; and
b) two engineered attenuated influenza B viruses consisting of:
i) B/Victoria having a mutant BM2 gene comprising SEQ ID NO: 9, and
ii) B/Yamagata having a mutant BM2 gene comprising SEQ ID NO: 9.